tradingkey.logo


tradingkey.logo


Ekso Bionics Holdings Inc

EKSO
4.860USD
+0.040+0.83%
終倀 12/19, 16:00ET15分遅れの株䟡
12.75M時䟡総額
損倱額盎近12ヶ月PER


Ekso Bionics Holdings Inc

4.860
+0.040+0.83%

詳现情報 Ekso Bionics Holdings Inc 䌁業名

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.

Ekso Bionics Holdings Incの䌁業情報


䌁業コヌドEKSO
䌚瀟名Ekso Bionics Holdings Inc
䞊堎日Apr 10, 2013
最高経営責任者「CEO」Davis (Scott G)
埓業員数61
蚌刞皮類Ordinary Share
決算期末Apr 10
本瀟所圚地101 Glacier Point
郜垂SAN RAFAEL
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号94901
電話番号15109841761
りェブサむトhttps://eksobionics.com/
䌁業コヌドEKSO
䞊堎日Apr 10, 2013
最高経営責任者「CEO」Davis (Scott G)

Ekso Bionics Holdings Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Steven A. Sherman
Mr. Steven A. Sherman
Executive Chairman of the Board
Executive Chairman of the Board
449.16K
+23.08%
Ms. Mary Ann Cloyd
Ms. Mary Ann Cloyd
Independent Director
Independent Director
25.23K
+166.00%
Mr. Jason C. Jones
Mr. Jason C. Jones
Chief Operating Officer
Chief Operating Officer
19.91K
-1.34%
Mr. Jerome Wong
Mr. Jerome Wong
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
17.56K
-6.59%
Ms. Deborah Lafer Scher
Ms. Deborah Lafer Scher
Independent Director
Independent Director
15.75K
--
Dr. Charles Li, Ph.D.
Dr. Charles Li, Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott G. Davis
Mr. Scott G. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Corinna E. Lathan
Dr. Corinna E. Lathan
Independent Director
Independent Director
--
--
Mr. Stephen Kilmer
Mr. Stephen Kilmer
Investor Relations
Investor Relations
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Steven A. Sherman
Mr. Steven A. Sherman
Executive Chairman of the Board
Executive Chairman of the Board
449.16K
+23.08%
Ms. Mary Ann Cloyd
Ms. Mary Ann Cloyd
Independent Director
Independent Director
25.23K
+166.00%
Mr. Jason C. Jones
Mr. Jason C. Jones
Chief Operating Officer
Chief Operating Officer
19.91K
-1.34%
Mr. Jerome Wong
Mr. Jerome Wong
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
17.56K
-6.59%
Ms. Deborah Lafer Scher
Ms. Deborah Lafer Scher
Independent Director
Independent Director
15.75K
--
Dr. Charles Li, Ph.D.
Dr. Charles Li, Ph.D.
Independent Director
Independent Director
--
--

収益内蚳

通貚: USD曎新時刻: Mon, Oct 6
通貚: USD曎新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
䌚瀟から関連デヌタがただ開瀺されおいたせん。
地域別USD
䌚瀟名
収益
比率
United States
1.02M
49.73%
Other EMEA
613.00K
29.80%
France
365.00K
17.74%
APAC
40.00K
1.94%
Other Americas
16.00K
0.78%
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Thu, Dec 4
曎新時刻: Thu, Dec 4
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Davis (Scott Gerald)
2.33%
Consolidated Portfolio Review Corp
1.91%
Citadel Advisors LLC
1.14%
The Vanguard Group, Inc.
1.04%
UBS Financial Services, Inc.
0.96%
他の
92.62%
株䞻統蚈
株䞻統蚈
比率
Davis (Scott Gerald)
2.33%
Consolidated Portfolio Review Corp
1.91%
Citadel Advisors LLC
1.14%
The Vanguard Group, Inc.
1.04%
UBS Financial Services, Inc.
0.96%
他の
92.62%
皮類
株䞻統蚈
比率
Individual Investor
6.59%
Investment Advisor
4.73%
Hedge Fund
1.57%
Investment Advisor/Hedge Fund
1.05%
Research Firm
0.33%
Family Office
0.03%
他の
85.70%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
64
261.39K
8.72%
--
2025Q3
67
261.39K
11.41%
+205.54K
2025Q2
64
55.85K
14.40%
-195.55K
2025Q1
62
251.40K
15.39%
-37.98K
2024Q4
61
283.25K
26.99%
-87.09K
2024Q3
58
370.34K
18.68%
+159.85K
2024Q2
61
145.58K
14.28%
+25.92K
2024Q1
67
120.72K
11.67%
-18.52K
2023Q4
71
95.15K
14.09%
+2.45K
2023Q3
71
92.88K
16.51%
-13.62K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Davis (Scott Gerald)
22.27K
0.85%
+7.04K
+46.23%
Mar 18, 2025
The Vanguard Group, Inc.
11.96K
0.46%
-27.61K
-69.77%
Jun 30, 2025
Li (Kecheng)
30.73K
1.18%
+15.75K
+105.11%
May 16, 2025
Lathan (Corinna)
25.61K
0.98%
+15.75K
+159.61%
May 16, 2025
Cloyd (Mary Ann)
25.23K
0.97%
+15.75K
+166.00%
May 16, 2025
Jones (Jason C)
14.90K
0.57%
+5.26K
+54.55%
Mar 18, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
May 19, 2025
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
日付
皮類
比率
May 19, 2025
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1

よくある質問

Ekso Bionics Holdings Incの䞊䜍5名の株䞻は誰ですか


Ekso Bionics Holdings Incの䞊䜍5名の株䞻は以䞋のずおりです。
Davis (Scott Gerald)は22.27K株を保有しおおり、これは党䜓の0.85%に盞圓したす。
The Vanguard Group, Inc.は11.96K株を保有しおおり、これは党䜓の0.46%に盞圓したす。
Li (Kecheng)は30.73K株を保有しおおり、これは党䜓の1.18%に盞圓したす。
Lathan (Corinna)は25.61K株を保有しおおり、これは党䜓の0.98%に盞圓したす。
Cloyd (Mary Ann)は25.23K株を保有しおおり、これは党䜓の0.97%に盞圓したす。

Ekso Bionics Holdings Incの株䞻タむプ䞊䜍3皮は䜕ですか


Ekso Bionics Holdings Incの株䞻タむプ䞊䜍3皮は、
Davis (Scott Gerald)
Consolidated Portfolio Review Corp
Citadel Advisors LLC

Ekso Bionics Holdings IncEKSOの株匏を保有しおいる機関の数はいく぀ですか


2025Q4時点で、Ekso Bionics Holdings Incの株匏を保有しおいる機関は64瀟あり、保有株匏の総垂堎䟡倀は玄261.39Kで、党䜓の8.72%を占めおいたす。2025Q3ず比范しお、機関の持ち株は-2.70%増加しおいたす。

Ekso Bionics Holdings Incの最倧の収益源は䜕ですか


FY2025Q2においお、--郚門がEkso Bionics Holdings Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™